Curevo Vaccine
Chemicals & Related Products · Washington, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
18911 N Creek Pkwy Ste 150, Bothell, Was...Phone Number
(206) 492-5722Website
www.curevovaccine.comRevenue
$10.6 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Curevo Vaccine
Curevo Vaccine is a clinical-stage biotech company focused on developing next-generation non-mRNA, adjuvanted subunit vaccines for unmet medical needs. Their lead product, amezosvatein, targets shingles and chickenpox and has shown promising results in clinical trials, aiming to improve vaccine tolerability and accessibility. By concentrating on one medical need at a time, they strive to bring more effective and better-tolerated vaccines to market quickly. The company aims to address issues such as vaccine hesitancy and accessibility, particularly for immunocompromised patients.Explore more
Curevo Vaccine Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Curevo Vaccine your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Curevo Vaccine has recently received funding, and reach out quickly before it becomes old news!
Check out if Curevo Vaccine is spiking on competitors!
Website visits: Recent activity has been detected on your website
Click to see if Curevo Vaccine had a recent Job posting/layoffs
Curevo Vaccine, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Curevo Vaccine has new funding data
Earning: See what the market has to say on Curevo Vaccine recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Curevo Vaccine
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Curevo Vaccine launches new products
Recommended Actions
Reach out to Masked Content who joined Curevo Vaccine as Masked Content
Find more new buyers
Compare Similar Companies to Curevo Vaccine
Compare insights from companies similar to Curevo Vaccine, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
<$5M
11-50
Private
$50.4M
1982
RS
Richard ShermanVice President, Business Development & Director & General Counsel
Company Profile Activity
Activity Insights
Curevo Vaccine is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Curevo Vaccine is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Curevo Vaccine.
Curevo Vaccine financials insights
Gather financial insights about Curevo Vaccine, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series A
$60M
Other Financing Round
$26M
2025
Other Financing Round
$110M
Curevo Vaccine Tech Stack
A closer look at the technologies used by Curevo Vaccine
See more technologies
Most Recent Scoops
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Pain Point
Project
, according to a high-level source in management & operations, is planning to remediate challenges related to ensuring data compliance. The organization plans to focus remediation efforts on training full-time employees (FTEs) on data compliance.
Pain Point, IT Audit / Compliance, Data Management, Training, Compliance, Operations
Project
, according to a high-level source in management & operations, is planning to begin initiatives related to GTM technologies and tools within six to nine months. The organization plans to develop an internal commercialization team to support these efforts.
Operations
Pain Point
Project
, according to a high-level source in management & operations, is planning to remediate challenges related to reaching targeted prospects. Curevo Vaccine is planning to increase headcount.
Pain Point, Lead Management, Customer Marketing, Operations
Project
Collaboration/Web Apps, Employee Relations, Operations
Curevo Vaccine News & Media
Curevo to be Acquired by Lilly to Advance Next-Generation Shingles Prevention
Curevo to be Acquired by Lilly to Advance Next-Generation Shingles PreventionGC Biopharma gets CMO rights to Curevo's shingles vaccine | The Pharmaletter
Yongyin, South Korea-based biopharma company GC Biopharma has signed an agreement with Seattle, USA-based biotech Curevo Vaccine to secure contract manufacturing (CMO) rights for amezosvatein (CRV-101), a recombinant shingles vaccine currently under clinical development.
Read more news
Top Chemicals & Related Products Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Curevo Vaccine
Sign Up For FreeTo access detailed company insights
Curevo Vaccine is a clinical-stage biotech company focused on developing next-generation non-mRNA, adjuvanted subunit vaccines for unmet medical needs. Their lead product, amezosvatein, targets shingles and chickenpox and has shown promising results in clinical trials, aiming to improve vaccine tolerability and accessibility. By concentrating on on... Read More
